Research Topics
| Paul William ManleySummaryAffiliation: Novartis Institutes for BioMedical Research Publications
| Collaborators |
Detail Information
Publications
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemiaPaul William Manley
Novartis Institutes for BioMedical Research, WKL 136 4 86, CH 4002 Basel, Switzerland
Biochim Biophys Acta 1754:3-13. 2005..Recent advances with these and other promising classes of new CML drugs are reviewed...
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinibPaul W Manley
Novartis Institutes for BioMedical Research, Basel, Switzerland
Bioorg Med Chem 18:6977-86. 2010....
Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesisPaul William Manley
Novartis Institutes of Biomedical Research, WKL 136 4 86, CH 4002 Basel, Switzerland
Biochim Biophys Acta 1697:17-27. 2004..This binding mode, similar to that observed for the anti-leukemia drug, imatinib in complex with c-Abl kinase, may be responsible for the high selectivity of AAL993 and provides valuable insight for the design of further compounds...
